Antibiotic resistance - Diagnostics and Vaccines

Diagnostics and Biomarkers to Guide Antibiotic Use Why Diagnostics Matter for Stewardship The fundamental problem in antibiotic prescribing is uncertainty. When a patient presents with fever and respiratory symptoms, clinicians cannot immediately determine whether the infection is bacterial or viral, which bacteria are responsible, or whether they're resistant to common drugs. This uncertainty leads to two major mistakes: treating viral infections with antibiotics (which won't help and wastes antibiotics) and using unnecessarily broad-spectrum antibiotics when narrower agents would work. Rapid diagnostic tests and biomarkers reduce this uncertainty, allowing clinicians to make more targeted decisions about when and what to prescribe. This is the cornerstone of antibiotic stewardship—using antibiotics more wisely to preserve their effectiveness. Rapid Diagnostic Tests Rapid diagnostic tests identify the presence of specific pathogens or distinguish between bacterial and viral infections within hours rather than days. The classic example comes from Hopkins and colleagues' 2017 research: they demonstrated that rapid malaria diagnostic tests significantly reduced inappropriate antibiotic prescribing in both public and private healthcare settings. Here's the mechanism: in malaria-endemic regions, fever is common, and clinicians often prescribe antibiotics empirically (without confirming a bacterial cause) because they're uncertain whether a bacterial infection is present. When rapid malaria tests became available, clinicians could quickly identify malaria as the cause of fever. Once malaria was diagnosed, they could prescribe antimalarial drugs specifically and avoid unnecessary antibiotics. This principle applies broadly: Rapid molecular tests can identify viral respiratory pathogens (influenza, respiratory syncytial virus, COVID-19) within hours, stopping unnecessary antibiotic use for viral colds Rapid bacterial identification tests can distinguish between streptococcal and viral sore throats Point-of-care tests for urinary tract infections can reduce treatment of asymptomatic bacteriuria (bacteria in urine without infection symptoms) The key benefit: faster results mean better decisions, less broad-spectrum use, and fewer antibiotics wasted on infections that don't need them. Procalcitonin as a Biomarker While rapid diagnostic tests identify what's causing an infection, procalcitonin helps answer a different question: does this patient actually have a bacterial infection that needs antibiotics? Procalcitonin is a protein produced by the body in response to bacterial infection. Viral infections typically trigger much lower procalcitonin levels. The 2017 study by Schuetz and colleagues showed that measuring procalcitonin levels could guide both the initiation and discontinuation of antibiotics for acute respiratory infections. Here's how it works in practice: Starting antibiotics: A patient with respiratory symptoms and normal procalcitonin (<0.1 ng/mL) likely has a viral infection—antibiotics should be withheld or not started. A patient with high procalcitonin (>0.5 ng/mL) likely has bacterial infection—antibiotics should be started. Stopping antibiotics: Even more importantly, if a patient started antibiotics but procalcitonin levels fall or remain low, it signals the bacterial infection is controlled or wasn't bacterial to begin with. The antibiotic course can be shortened or stopped. This typically reduces antibiotic exposure by several days while maintaining good outcomes. Why this matters: Shorter courses mean fewer side effects, less disruption of normal bacteria (microbiome), and lower costs. For a patient who might otherwise receive 7-10 days of antibiotics, procalcitonin-guided therapy might reduce this to 3-4 days. Important limitation: Procalcitonin is not a perfect diagnostic test. It indicates the likelihood of bacterial infection but cannot identify which specific bacteria are present or what they're resistant to. It works best as a complement to clinical judgment, not a replacement. Molecular and Genotypic Resistance Detection Even with a confirmed bacterial infection, clinicians face another critical uncertainty: which antibiotics will actually work against this particular bacterium? Traditionally, this required growing the bacterium in culture (which takes 48-72 hours) and then testing its susceptibility to different antibiotics (another 24-48 hours). By then, 3-5 days have passed. Molecular diagnostics bypass this slow process. As Banerjee and Patel reviewed in 2023, molecular tests can directly detect antibiotic-resistance genes from clinical samples—blood, sputum, urine, or cerebrospinal fluid—often within hours. How this works: Gene-based detection: These tests use polymerase chain reaction (PCR) or similar techniques to identify DNA sequences encoding resistance genes. For example: Detecting mecA gene → indicates methicillin resistance in Staphylococcus aureus (MRSA) Detecting carbapenemase genes → indicates resistance to last-resort beta-lactam antibiotics Detecting vancomycin resistance genes → identifies organisms resistant to vancomycin Organism identification plus resistance detection: Some molecular panels simultaneously identify the bacterial species and its major resistance genes, all within hours. Clinical impact: A clinician can switch from broad-spectrum antibiotics (which cover resistant organisms but have more side effects) to narrow-spectrum antibiotics the same day, rather than waiting days for culture results. For serious infections like sepsis, this speed can be life-saving. For all infections, it reduces unnecessary exposure to broad-spectrum agents. Trade-off: These tests are more expensive than traditional culture methods and may detect genes that aren't actually being expressed (a bacterium can carry a resistance gene but not use it). However, the clinical benefits and stewardship advantages increasingly justify the cost. Vaccines and Their Relationship to Antibiotic Resistance Why Vaccines Matter in the Resistance Problem At first glance, vaccines seem unrelated to antibiotic resistance—one prevents infection, the other treats it. But epidemiologically, they're connected as alternative strategies to manage infectious disease. Understanding this relationship clarifies why vaccines are increasingly recognized as crucial to combating antibiotic resistance. Vaccine Impact on Resistance Evolution A counterintuitive observation: drug resistance evolves readily and quickly, while vaccine resistance is rare. Kennedy and Read's 2017 analysis explained why. The key difference lies in selective pressure: When antibiotics are used, they kill non-resistant bacteria but allow resistant bacteria to survive and reproduce. Resistant bacteria then dominate the bacterial population. This is straightforward Darwinian selection—resistance confers a survival advantage in the presence of the drug. With vaccines, the selective pressure works differently: How vaccine "resistance" would evolve: Theoretically, a bacterial variant could mutate to evade the immune response triggered by a vaccine, just as bacteria can mutate to resist antibiotics. However, this is rarely observed. Why? The critical difference is that a vaccine-resistant variant would need to evade the immune system while still maintaining the ability to cause disease. Many viral and bacterial proteins that vaccines target are actually essential for the pathogen's survival or virulence. If a bacterium mutates the vaccine-target protein to evade immunity, it may lose critical function. For example, if a pneumococcal vaccine targets a protein essential for the bacterium to adhere to respiratory cells, a mutant that evades the vaccine would likely be unable to attach and cause infection—it would be less fit, not more fit. With antibiotics, by contrast, a resistance mutation can be acquired without losing virulence. A bacterium can become resistant to penicillin while remaining fully capable of causing disease. Practical consequence: Vaccines create durable protection (immunity can last years or decades), while antibiotic resistance requires constant development of new drugs to stay ahead of evolving resistance. This makes vaccines far more sustainable tools for infection control. <extrainfo> Vaccine Development Challenges While vaccines are strategically superior to antibiotics for long-term disease management, developing new vaccines is challenging. Fowler and Proctor (2014) examined obstacles to a successful Staphylococcus aureus vaccine—a bacterium for which we still lack an effective vaccine despite decades of research. Key challenges include: Antigenic variability: S. aureus has multiple different surface proteins (antigens). A vaccine targeting one protein might not protect against all strains. Developing a vaccine that covers all major variants requires targeting multiple antigens simultaneously, which is technically complex. Immune evasion mechanisms: S. aureus produces proteins and enzymes that directly interfere with the immune response—it inactivates complement proteins, inhibits white blood cells, and degrades antibodies. A vaccine must overcome these evasion strategies, making it difficult to generate protective immunity. Lack of natural immunity: Unlike some bacteria, recovering from S. aureus infection doesn't reliably generate immunity to future infections. This suggests natural protective mechanisms are weak, making vaccine development harder. These challenges illustrate why vaccines, while strategically superior, cannot be developed instantly when resistance emerges. This underscores the importance of stewardship—using existing antibiotics wisely to extend their useful lifespan while longer-term vaccine solutions are developed. </extrainfo>